Soluble Fas Ligand Inhibits Angiogenesis in Rheumatoid Arthritis

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2007 Apr 27

PMID 17459170

Citations 14

Authors

Wan-Uk Kim

Seung-Ki Kwok

Kyung-Hee Hong

Seung-Ah Yoo

Jin-Sun Kong

Jongseon Choe

Chul-Soo Cho

Affiliations

Soon will be listed here.

Abstract

The characteristics of rheumatoid arthritis (RA) pathology include the infiltration of inflammatory leukocytes, the proliferation of synovial cells, and the presence of extensive angiogenesis, referred to as rheumatoid pannus. Fas ligand is critical to the homeostatic regulation of the immune response, but its role in the angiogenic process of RA remains to be defined. In this study, we investigated whether soluble Fas ligand (sFasL) induces synoviocyte apoptosis and regulates angiogenesis of endothelial cells in RA. The levels of sFasL were elevated in the synovial fluids of RA patients when compared to those of osteoarthritis (OA) patients, and they correlated inversely with vascular endothelial growth factor165 (VEGF165) concentrations. sFasL, ranging from 10 to 100 ng/ml, induced the apoptosis of RA fibroblast-like synoviocytes (FLS) in vitro, and thereby decreased VEGF165 production. In addition, sFasL inhibited VEGF165-induced migration and chemotaxis of endothelial cells to basal levels in a manner independent of the Fas-mediated cell death. sFasL dose-dependently suppressed the VEGF165-stimulated increase in pAkt expression in endothelial cells, which might be associated with its anti-migratory effect on endothelial cells. Moreover, sFasL strongly inhibited neovascularization in the Matrigel plug in vivo. Our data suggest that sFasL shows anti-angiogenic activity within RA joints not only by inducing apoptosis of VEGF165-producing cells but also by blocking VEGF165-induced migration of endothelial cells, independent of Fas-mediated apoptosis.

Citing Articles

Apoptosis, Autophagy, NETosis, Necroptosis, and Pyroptosis Mediated Programmed Cell Death as Targets for Innovative Therapy in Rheumatoid Arthritis.

Zhao J, Jiang P, Guo S, Schrodi S, He D Front Immunol. 2022; 12:809806.

PMID: 35003139 PMC: 8739882. DOI: 10.3389/fimmu.2021.809806.

Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2.

Jeong D, Kim H, Kim H, Kang M, Jung H, Oh Y Elife. 2021; 10.

PMID: 34223817 PMC: 8257255. DOI: 10.7554/eLife.48840.

A systematic review of preclinical studies on the efficacy of taurine for the treatment of rheumatoid arthritis.

Malek Mahdavi A, Javadivala Z Amino Acids. 2021; 53(6):783-800.

PMID: 33929638 DOI: 10.1007/s00726-021-02988-8.

Encapsulated Mesenchymal Stromal Cell Microbeads Promote Endogenous Regeneration of Osteoarthritic Cartilage Ex Vivo.

Sahu N, Agarwal P, Grandi F, Bruschi M, Goodman S, Amanatullah D Adv Healthc Mater. 2021; 10(8):e2002118.

PMID: 33434393 PMC: 10591520. DOI: 10.1002/adhm.202002118.

Decoy Receptor 3 Promotes Preosteoclast Cell Death via Reactive Oxygen Species-Induced Fas Ligand Expression and the IL-1/IL-1 Receptor Antagonist Pathway.

Peng Y, Peng C, Lin Y, Lin G, Huang S, Chen S Mediators Inflamm. 2020; 2020:1237281.

PMID: 32587467 PMC: 7303756. DOI: 10.1155/2020/1237281.

References

Sata M, Suhara T, Walsh K . Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol. 2000; 20(2):309-16. DOI: 10.1161/01.atv.20.2.309. View

Delleva R, Ambrosini C, Minghelli S, Noonan D, Albini A, Ferrari N . The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis. 2006; 28(2):404-13. DOI: 10.1093/carcin/bgl162. View

Mogi M, Fukuo K, Yang J, Suhara T, Ogihara T . Hypoxia stimulates release of the soluble form of fas ligand that inhibits endothelial cell apoptosis. Lab Invest. 2001; 81(2):177-84. DOI: 10.1038/labinvest.3780225. View

Choi C, Xu X, Oh J, Lee S, Gillespie G, Park H . Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res. 2001; 61(7):3084-91. View

Lee M, Moon E, Lee S, Kim M, Kim K, Kim Y . Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res. 2001; 61(8):3290-3. View

Lee S, Joo Y, Kim W, Min D, Min J, Park S . Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol. 2001; 19(3):321-4. View

Ahn J, Park S, Cho H, Lee M, Yoon J, Vilcek J . Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression. J Biol Chem. 2001; 276(50):47100-6. DOI: 10.1074/jbc.M107385200. View

Janin A, Deschaumes C, Daneshpouy M, Estaquier J, Micic-Polianski J, Akarid K . CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood. 2002; 99(8):2940-7. DOI: 10.1182/blood.v99.8.2940. View

Okura T, Watanabe S, Jiang Y, Nakamura M, Takata Y, Yang Z . Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens. 2002; 20(5):895-8. DOI: 10.1097/00004872-200205000-00024. View

10.

Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones P . Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol. 2003; 30(2):260-8. View

11.

Baier A, Meineckel I, Gay S, Pap T . Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol. 2003; 15(3):274-9. DOI: 10.1097/00002281-200305000-00015. View

12.

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

13.

Lee H, Ferguson T . Biology of FasL. Cytokine Growth Factor Rev. 2003; 14(3-4):325-35. DOI: 10.1016/s1359-6101(03)00028-5. View

14.

Autiero M, Luttun A, Tjwa M, Carmeliet P . Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003; 1(7):1356-70. DOI: 10.1046/j.1538-7836.2003.00263.x. View

15.

Kawasaki K, Smith Jr R, Hsieh C, Sun J, Chao J, Liao J . Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol. 2003; 23(16):5726-37. PMC: 166338. DOI: 10.1128/MCB.23.16.5726-5737.2003. View

16.

Panka D, Mier J . Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem. 2003; 278(39):37632-6. DOI: 10.1074/jbc.M307339200. View

17.

Koch A . Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis. 2003; 62 Suppl 2:ii60-7. PMC: 1766740. DOI: 10.1136/ard.62.suppl_2.ii60. View

18.

Filippatos G, Ang E, Gidea C, Dincer E, Wang R, Uhal B . Fas induces apoptosis in human coronary artery endothelial cells in vitro. BMC Cell Biol. 2004; 5:6. PMC: 331398. DOI: 10.1186/1471-2121-5-6. View

19.

Li N, Nie H, Yu Q, Zhang J, Ma A, Shen B . Role of soluble Fas ligand in autoimmune diseases. World J Gastroenterol. 2004; 10(21):3151-6. PMC: 4611260. DOI: 10.3748/wjg.v10.i21.3151. View

20.

Yonehara S, Crump 3rd W, Grimm E . DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 1992; 140(1):197-205. DOI: 10.1016/0008-8749(92)90187-t. View